Rajesh Shrotriya
Direktor/Vorstandsmitglied bei GT BIOPHARMA, INC.
Vermögen: - $ am 31.05.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Luigi Lenaz | M | 83 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA.
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 26 Jahre |
Michael Breen | M | 61 | 3 Jahre | |
Abraham Noah Oler | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 Jahre |
Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 Jahre |
Terrence Wright | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Charles Casamento | M | 78 | 1 Jahre | |
Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 Jahre |
Keith M. McGahan | M | - | 8 Jahre | |
Bruce Wendel | M | 70 | 4 Jahre | |
James E. Shields | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 Jahre |
Daniel Byron | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Michael A. Grabow | M | - | 11 Jahre | |
Greg McKinley | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
John Midby | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jeffrey Shaw | M | 65 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Johnny Ribeiro | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Raj Chanderraj | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jennie Dorsey | F | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Greg Fullmer | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jim Medick | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Daniel Giraldo | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Daniel Tuntland | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Bill Drobkin | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Corey Sanders | M | 60 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Thomas Morton | M | 55 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
John F. O'Reilly | M | 78 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Roberto R. Denis | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
David R. Belding | M | 78 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | 32 Jahre |
Robert C. Melendres | M | 59 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Michael W. Yackira | M | 72 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Blake Sartini | M | 65 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
James Murren | M | 62 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Mark Frissora | M | 68 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 Jahre |
Tony A. Marnell | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Frank E. Martin | M | 77 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
William J. Paulos | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
William C. Wortman | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Brian Greenspun | M | 77 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
John Guedry | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Peter Thomas | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jeffrey Miller | M | - | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Anthony Cataldo | M | 73 | 12 Jahre | |
Thomas Riga | M | 48 | 10 Jahre | |
Joseph W. Turgeon | M | 66 | 9 Jahre | |
Samuel Gulko | M | 92 | 6 Jahre | |
Elly Ryu | F | 43 | 10 Jahre | |
Gavin Choy | M | - | - | |
Kurt Gustafson | M | 55 | 9 Jahre | |
Brett Scott | M | 73 | - | |
Gregory Berk | M | 66 | 2 Jahre | |
Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
Robert Fralin | M | - | - | |
Alan Urban | M | 55 | 1 Jahre | |
Krishan K. Arora | M | 83 | 3 Jahre | |
Manu Ohri | M | 68 | 2 Jahre | |
Dilip J. Mehta | M | 91 | 7 Jahre | |
Dolatrai Vyas | M | 80 | 9 Jahre | |
Anthony Maida | M | 59 | 16 Jahre | |
Gilles Gagnon | M | 70 | - | |
Raymond Cohen | M | 65 | 7 Jahre | |
Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
George Ng | M | 49 | 3 Jahre | |
Ronald Spair | M | 58 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 2 Jahre |
David Stout | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 Jahre |
Shyam K. Kumaria | M | 74 | - | |
Anton G. Gueth | M | 67 | 1 Jahre | |
Hari Babu Varshney | M | 79 |
Dr. Bhim Rao Ambedkar University
| 6 Jahre |
David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
Michael Handelman | M | 65 | 1 Jahre | |
Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
Leonard M. Greenstein | M | 48 | 7 Jahre | |
Ricardo J. Gonzalez | M | 53 | 6 Jahre | |
Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 Jahre |
Charles N. Blitzer | M | 83 |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 7 Jahre |
Amit Bhupendra Shah | M | 57 | 3 Jahre | |
Guru Reddy | M | - | - | |
Jennifer Carver | F | 70 | 2 Jahre | |
Antonis Koutsoukos | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
Steven Fruchtman | M | 73 | 2 Jahre | |
Hemant Kumar | M | - |
Dr. Bhim Rao Ambedkar University
| 4 Jahre |
Vijay Prakash Agarwal | M | 80 |
Dr. Bhim Rao Ambedkar University
| 1 Jahre |
Christopher Nardo | M | 59 | 5 Jahre | |
Bruce Goldsmith | M | 58 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 Jahre |
Thomas V. Girardi | M | 84 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 11 Jahre |
Sushil Kanubhai Shah | M | 77 |
The Grant Government Medical College
| 3 Jahre |
Anil Kumar Bhattacharya | M | 90 |
Dr. Bhim Rao Ambedkar University
| 3 Jahre |
George Uy | M | 67 | 4 Jahre | |
Sanjeev Gurunath Redkar | M | 56 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 13 Jahre |
Denise Landry | F | - |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 13 Jahre |
Mitchell P. Cybulski | M | 77 | - | |
George Tidmarsh | M | 64 | 1 Jahre | |
Michael A. Adam | M | 66 | 2 Jahre | |
John McManus | M | 60 | 1 Jahre | |
Walter J. Lack | M | 76 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 11 Jahre |
Luke Seikkula | M | 60 | 3 Jahre | |
Amar P. Singh | M | 65 | 1 Jahre | |
Bruce K. Bennett | M | 73 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 Jahre |
Audrey F. Jakubowski | M | 81 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 9 Jahre |
Kathy Quandt | F | - | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 95 | 95,00% |
Indien | 5 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Rajesh Shrotriya
- Persönliches Netzwerk